2013
DOI: 10.1167/tvst.2.7.4
|View full text |Cite
|
Sign up to set email alerts
|

Proceedings of the First International Optogenetic Therapies for Vision Symposium

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
8
0
2

Year Published

2014
2014
2019
2019

Publication Types

Select...
6
2
1

Relationship

0
9

Authors

Journals

citations
Cited by 15 publications
(10 citation statements)
references
References 60 publications
0
8
0
2
Order By: Relevance
“…With the combined use of these proteins and specific light wavelengths, it is possible to study the behavior of a specific area of the human brain in different conditions [6]. The first trials involving optogenetic techniques were carried out in the field of ophthalmology [7]. These trials mainly involved the Opsins family.…”
Section: Molecular Pathways In Optogeneticsmentioning
confidence: 99%
“…With the combined use of these proteins and specific light wavelengths, it is possible to study the behavior of a specific area of the human brain in different conditions [6]. The first trials involving optogenetic techniques were carried out in the field of ophthalmology [7]. These trials mainly involved the Opsins family.…”
Section: Molecular Pathways In Optogeneticsmentioning
confidence: 99%
“…77 The opening of these channels is modulated by light and the flux of ions across cell membranes creates an action potential, analogous to a neurone discharging. The attraction of optogenetics for inherited retinal diseases lies in the structured relay system that exists with the mammalian retina, and disorders affecting the outer retina lend themselves particularly well to visual restoration using this technique (figure 1).…”
Section: Retinal Neurodegenerative Diseasesmentioning
confidence: 99%
“…This is compounded with the difficulty in determining the correct levels of opsin expression, as overexpression has been demonstrated to have cytotoxic effects. The FDA has recently cleared an application for optogenetic gene therapy for the treatment of RP, which will allow clinical trials in humans to commence (Francis et al, 2013 ; RetroSense, 2015 ). The treatment aims to restore photosensitivity of photoreceptors, bypassing the need for a separate light activation source.…”
Section: Clinical Challenges For Optogenetic Augmentationmentioning
confidence: 99%